The Study
Genetic Ablation of p16 Mitigates Premature Osteoporosis Induced by PTHrP Nuclear Localization Sequence and C-terminal Deletion through Inhibition of Cellular Senescence.
This study looked at mice with a broken bone gene and saw that when they also removed another gene called p16, their bones got a little better. But it didn't prove that p16 was the direct cause — it just showed the two things happened together in these special mice.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Mice with a broken PTHrP gene get very sick, have tiny bones, and die young. When scientists turned off another gene called p16, which makes cells stop growing, the mice grew bigger bones, moved better, and lived longer.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 512 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — if this works in humans, turning off p16 could help treat rare childhood bone diseases and maybe even age-related osteoporosis.
- 2Lifespan increased from 1–3 weeks to 2–4 weeks; bone volume increased by 40–60%; senescence markers in bone stem cells dropped by ~50%; chondrocyte growth and bone formation markers improved significantly.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Stem cells
Year
2024
Authors
Yongli Han, Wanxin Qiao, Qi Xue, D. Miao, Zhan Dong
Related Content
Claims (6)
Removing cells that express the p16 protein in mice results in better tissue function and longer life.
In genetically modified mice with a specific PTHrP mutation, removing the p16 gene results in longer lifespan, greater body weight, improved skeletal growth, and higher bone volume due to reduced cellular senescence in bone marrow stem cells and bone-forming cells.
In mice with a specific genetic mutation affecting bone growth, removing the p16 gene results in higher bone density and increased activity of bone-forming cells.
In mice with a specific genetic dysfunction affecting bone development, removing the p16 gene reduces markers of cellular aging in bone marrow stem cells by about half and increases their ability to form bone tissue.
In mice with a specific genetic disruption affecting bone development, removing the p16 gene lowers markers of oxidative stress and DNA damage in bone tissue and increases the presence of certain antioxidant proteins.
In mice with a specific genetic disruption affecting bone growth, removing the p16 gene leads to more chondrocyte cell division in growth plates, wider growth plates, and improved skeletal growth.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.